Abstract: The invention relates to a (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a substance as a colloid of fine solid and/or liquid particles in a fluid. 1. According to the invention the substance is dispensed in form of a parenteral administration into a human and/or animal body.

Abstract: Methods of producing non-human animal models of corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal ectatic diseases.

Abstract: Electrochemical processes and systems for preserving perishable food are described. The process and system allow for the preservation of perishable food in the presence of water moisture, melanin, or a precursor, derivative, analog, or variant of melanin, and electromagnetic energy, such as visible or invisible light energy. There exists a need in the art for improved methods and processes for preserving perishable foods that overcome certain disadvantages associated with known methods for preserving perishable food, such as addition of preservatives, refrigeration/freezing, drying/dehydration of food, and storage under vacuum. The invention satisfies this need by providing a process and system for preserving perishable food in the presence of water moisture, electromagnetic energy, and melanin, melanin precursors, melanin derivatives, melanin analogs, or melanin variants.

Abstract: A solid-state battery is provided. The battery includes a melanin structure formed of at least one melanin material embedded in an inert material, and first and second metal bands which serve as first and second electrodes, respectively. The melanin material is selected from the group consisting of melanin, melanin precursors, melanin derivatives, melanin analogs and melanin variants. The solid-state battery does not need to be recharged or reloaded.

Abstract: The invention relates to a (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a substance as a colloid of fine solid and/or liquid particles in a fluid. 1. According to the invention the substance is dispensed in form of a parenteral administration into a human and/or animal body.

Abstract: A solid-state battery is provided. The battery includes a melanin structure formed of at least one melanin material embedded in an inert material, and first and second metal bands which serve as first and second electrodes, respectively. The melanin material is selected from the group consisting of melanin, melanin precursors, melanin derivatives, melanin analogs and melanin variants. The solid-state battery does not need to be recharged or reloaded.

Abstract: Methods for reducing and regulating the acidification of water are provided. The method for reducing the acidification of water includes contacting at least one melanin material with the water and catalyzing a reaction between the water, CO2 and/or bicarbonate that produces glucose and increases pH of the water. The acidification of water is regulated by removing the at least one melanin material from the water once a desired pH of the water has been attained. The methods for reducing and regulating the acidification of water are particularly suited for the treatment of seawater that has been acidified by naturally occurring or artificially initiated reactions that increase free hydrogen ions in water, for example absorption of atmospheric carbon dioxide.

Abstract: A textile has an active outside surface and an active inside surface including optical fibers covering at least partially the active outside surface, wherein the active outside surface captures light, which is transmitted by the optical fibers to the active inside surface.

Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

Abstract: An electrochemical process and system for producing glucose are described. The process and system allow for the production of glucose from carbon dioxide and water, requiring only melanin, or a precursor, derivative, analog, or variant of melanin, and electromagnetic energy, such as visible or invisible light energy.

Abstract: Methods of producing non-human animal models of corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal ectatic diseases.

Abstract: Methods of producing non-human animal models of corneal angiogenesis and corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal angiogenesis and corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal angiogenesis and corneal ectatic diseases.

Abstract: Methods of fertilizing soil, and of increasing a crop yield, plant growth, and rate of seed germination using melanin, or a melanin precursor, derivative, or analog are provided. The methods described herein require water, melanin, or a melanin precursor, derivative, or analog, and a source of electromagnetic energy, such as visible or invisible light energy, to catalyze the electrolysis of water. The electrolysis of water causes the release of diatomic hydrogen into the soil, resulting in fertilization of the soil. Also provided are fertilized soil compositions.

Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

Abstract: Uses of melanin and its derivatives, analogs, and precursors for the treatment and prevention of ocular diseases, disorders, and conditions, are described. Melanin, or a derivative, analog, or precursor thereof, such as synthetic melanin or natural melanin, is applied to the eye by topical application or injection. Examples of ocular diseases, disorders, and conditions that can be treated or prevented by the methods described herein include hyperemia, leukoplakia, corneal angiogenesis, and corneal keratoconus.

Abstract: Methods for reducing and regulating the acidification of water are provided. The method for reducing the acidification of water includes contacting at least one melanin material with the water and catalyzing a reaction between the water, CO2 and/or bicarbonate that produces glucose and increases pH of the water. The acidification of water is regulated by removing the at least one melanin material from the water once a desired pH of the water has been attained. The methods for reducing and regulating the acidification of water are particularly suited for the treatment of seawater that has been acidified by naturally occurring or artificially initiated reactions that increase free hydrogen ions in water, for example absorption of atmospheric carbon dioxide.

Abstract: Methods of treating renal failure are described. In particular, methods of treating renal failure by administration of pharmaceutical composition including a mixture of nicotine and salicylic acid are described.

Abstract: A textile has an active outside surface and an active inside surface including optical fibers covering at least partially the active outside surface, wherein the active outside surface captures light, which is transmitted by the optical fibers to the active inside surface.

Abstract: Uses of melanin and its derivatives, analogs, and precursors for the treatment and prevention of ocular diseases, disorders, and conditions, are described. Melanin, or a derivative, analog, or precursor thereof, such as synthetic melanin or natural melanin, is applied to the eye by topical application or injection. Examples of ocular diseases, disorders, and conditions that can be treated or prevented by the methods described herein include hyperemia, leukoplakia, corneal angiogenesis, and corneal keratoconus.